<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Fragmin; Dalteparin" /><meta name="IX" content="Fragmin; Dalteparin" /><title>Fragmin®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2774.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2774.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2774.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="2760.htm">2.8 Anticoagulants and protamine</a> &gt; <a href="2761.htm">2.8.1 Parenteral anticoagulants</a> &gt; <a href="2772.htm">Low molecular weight heparins</a> &gt; <a href="2773.htm">DALTEPARIN SODIUM</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2772.htm" title="Previous: Low molecular weight heparins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2775.htm" title="Next: ENOXAPARIN SODIUM">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a396006.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dalteparin Sodium</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Antithrombotic Agents 20:12 &gt; Anticoagulants 20:12.04 &gt; Heparins 20:12.04.16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22569-e.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Dalteparin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Dalteparin</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="2772.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Low molecular weight heparins</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants</p></div></li><li><a href="2773.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DALTEPARIN SODIUM</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants &gt; Low molecular weight heparins</p></div></li></ul><ul><li><h3>BNF for Children (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/2772.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Low molecular weight heparins</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/2773.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DALTEPARIN SODIUM</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants &gt; Low molecular weight heparins</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/2774.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Fragmin®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 2 Cardiovascular system &gt; 2.8 Anticoagulants and protamine &gt; 2.8.1 Parenteral anticoagulants &gt; Low molecular weight heparins &gt; DALTEPARIN SODIUM</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a502002.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dalteparin Sodium</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; D</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/d01-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dalteparin sodium</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; D</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/14676-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dalteparin Sodium</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Cardiovascular Drugs &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02805.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Dalteparin</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DA</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E20E3E0R0D895.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Dalteparin</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_2773">DALTEPARIN SODIUM</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i226.htm" title="Go to appendix 1">Dalteparin</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see notes above and under preparations</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">see under <a title="target-block: Heparin cautions" href="2762.htm#_2762.1"><span>Heparin</span></a> and notes above</p></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">see under <a title="target-block: Heparin contra-indications" href="2762.htm#_2762.2"><span>Heparin</span></a></p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">dose reduction may be required in severe impairment</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">risk of bleeding may be increased—dose reduction, and
monitoring of anti-Factor Xa, may be required; use of unfractionated
heparin may be preferable</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">not known to be harmful; multidose vial contains
benzyl alcohol—manufacturer advises avoid; see also <a title="BNF:target-block: heparin in pregnancy" href="11290.htm#_11290.1">Pregnancy</a></p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">no information available</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">see under <span>Heparin</span></p></div><div class="cAF"><h2>Dose</h2> <p class="cR">See under preparations below</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li class="jN" id="_2774" style="margin: 0 0 0 20px;"><h1 class="title">Fragmin®<span> (<a href="appendix-112803-P.htm#m163">Pharmacia</a>)</span> <a href="204285.htm" title="Report adverse reaction(s)"><img class="cK" src="images/blacktri_s.png" alt="Black triangle" /></a> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Injection</span> (single-dose syringe), <span>dalteparin sodium</span> 12 500 units/mL, net price 2500-unit
(0.2-mL) syringe = £1.86; 25 000 units/mL, 5000-unit (0.2-mL) syringe
= £2.82, 7500-unit (0.3-mL) syringe = £4.23, 10 000-unit (0.4-mL)
syringe = £5.65, 12 500-unit (0.5-mL) syringe = £7.06, 15 000-unit
(0.6-mL) syringe = £8.47, 18 000-unit (0.72-mL) syringe = £10.16<div class="cAQ"><div class="cAF"><h2>Dose</h2> <p class="cAF">prophylaxis of deep-vein thrombosis, in surgical patients, <span class="cU">by subcutaneous injection</span>, moderate risk, 2500 units 1–2
hours before surgery then 2500 units every 24 hours; high risk, 2500 units
1–2 hours before surgery, then 2500 units 8–12 hours later (<i>or</i> 5000 units on the evening before surgery, then 5000 units
on the following evening), then 5000 units every 24 hours</p></div><div class="cAF"><p class="cAF">Prophylaxis of deep-vein thrombosis in medical patients, <span class="cU">by subcutaneous injection</span>, 5000 units every 24 hours</p></div><div class="cAF"><p class="cAF">Treatment of deep-vein thrombosis and of pulmonary embolism, <span class="cU">by subcutaneous injection</span>, as a single daily dose, <span class="cAK">adult</span> body-weight under 46 kg, 7500 units daily;
body-weight 46–56 kg, 10 000 units daily; body-weight 57–68 kg, 12 500 units
daily; body-weight 69–82 kg, 15 000 units daily; body-weight 83 kg
and over, 18 000 units daily, with oral anticoagulant treatment until
adequate oral anticoagulation established; monitoring of anti-Factor
Xa not usually required; for patients at increased risk of haemorrhage,
see below</p></div><div class="cAF"><p class="cAF">Treatment of venous thromboembolism in pregnancy [unlicensed
indication], <span class="cU">by subcutaneous injection</span>, early pregnancy
body-weight under 50 kg, 5000 units twice daily; body-weight 50–70 kg,
6000 units twice daily; body-weight 70–90 kg, 8000 units twice daily;
body-weight over 90 kg, 10 000 units twice daily</p></div><div class="cAF"><p class="cAF">Extended treatment and prophylaxis of venous thromboembolism
in patients with solid tumours, <span class="cU">by subcutaneous injection</span>, once daily for 30 days, <span class="cAK">adult</span> body-weight
40–45 kg, 7500 units daily; body-weight 46–56 kg, 10 000 units daily;
body-weight 57–68 kg, 12 500 units daily; body-weight 69–82 kg, 15 000 units
daily; body-weight 83 kg and over, 18 000 units daily; <i>then</i> once daily for a further 5 months, <span class="cU">by subcutaneous injection</span>, <span class="cAK">adult</span> body-weight 40–56 kg, 7500 units
daily; body-weight 57–68 kg, 10 000 units daily; body-weight 69–82 kg,
12 500 units daily; body-weight 83–98 kg, 15 000 units daily; body-weight
99 kg and over, 18 000 units daily; interrupt treatment or reduce
dose in chemotherapy-induced thrombocytopenia—consult product literature</p></div></div></div><div class="cAY"><span class="cAB">Injection</span>, <span>dalteparin sodium</span> 2500 units/mL (for subcutaneous or intravenous use), net price 4-mL
(10 000-unit) amp = £5.12; 10 000-units/mL (for subcutaneous or intravenous
use), 1-mL (10 000-unit) amp = £5.12; 25 000 units/mL (for subcutaneous
use only), 4-mL (100 000-unit) vial = £48.66<div class="cAO"><span class="cAG">Excipients </span> include benzyl alcohol
(in 100 000-unit/4 mL multidose vial) (avoid in neonates, see <a title="BNF:target-block: Excipients" href="29404.htm#_120000">Excipients</a>)</div><div class="cAQ"><div class="cAF"><h2>Dose</h2> <p class="cAF">treatment of deep-vein thrombosis and of pulmonary embolism, <span class="cU">by subcutaneous injection</span>, 200 units/kg (max. 18 000 units)
as a single daily dose (<i>or</i> 100 units/kg twice daily
if increased risk of haemorrhage) until adequate oral anticoagulation
established</p><div class="cAV"><h3>Note</h3> <p class="cAX">For monitoring, blood should
be taken 3–4 hours after a dose (recommended plasma concentration
of anti-Factor Xa 0.5–1 unit/mL); monitoring not required for once-daily
treatment regimen and not generally necessary for twice-daily regimen</p></div></div><div class="cAF"><p class="cAF">Unstable coronary artery disease, <span class="cU">by subcutaneous
injection</span>, 120 units/kg every 12 hours (max. 10 000 units
twice daily) for 5–8 days</p></div><div class="cAF"><p class="cAF">Prevention of clotting in extracorporeal circuits, consult
product literature</p></div></div></div><div class="cAY"><span class="cAB">Injection</span> (graduated syringe), <span>dalteparin sodium</span> 10 000 units/mL, net price 1-mL (10 000-unit)
syringe = £5.65<div class="cAQ"><div class="cAF"><h2>Dose</h2> <p class="cAF">unstable coronary artery disease (including non-ST-segment-elevation
myocardial infarction), <span class="cU">by subcutaneous injection</span>,
120 units/kg every 12 hours (max. 10 000 units twice daily) for up
to 8 days; beyond 8 days (if awaiting angiography or revascularisation)
women body-weight less than 80 kg and men less than 70 kg, 5000 units
every 12 hours, women body-weight greater than 80 kg and men greater
than 70 kg, 7500 units every 12 hours, until day of procedure (max.
45 days)</p></div></div></div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2772.htm">Previous: Low molecular weight heparins</a> | <a class="top" href="2774.htm#">Top</a> | <a accesskey="]" href="2775.htm">Next: ENOXAPARIN SODIUM</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>